How upregulating α7β1 integrin might compensate for the lack of dystrophin and DGC in individuals living with Duchenne or Beckers Muscular Dystrophy.
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
Sarcomatrix Therapeutics Corp.’s exclusive research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to advance small molecules promoting muscle regeneration.
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
Laminin-111 is a potential first-in-class protein replacement therapy directed to LAMA2-Related Dystrophies – patients, currently in investigational preclinical studies
Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.
